866-997-4948(US-Canada Toll Free)

Inflammatory Skin Diseases Drug Development Pipeline Review, 2018

Published By :

GBI Research

Published Date : May 2018

Category :

Pharmaceutical

No. of Pages : 112 Pages

Inflammatory Skin Diseases Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for inflammatory skin disorders and comprehensive information on the therapeutics under development and key players involved in therapeutic development for acne vulgaris, rosacea and chronic urticaria (also known as hives). It also features dormant and discontinued products.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. There are 60 products in development for this indication, and companies operating in this space include Cassiopea and Elorac.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. There are 18 products in development for this indication, and companies operating in this space include Dermata Therapeutics and Promius Pharma.

Chronic urticaria, also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. There are 17 products in development for this indication, and companies operating in this space include GlaxoSmithKline and Novartis.

Molecular targets acted on by products in development for inflammatory skin disorders include cytokines, ribosomal RNA and retinoic acid receptors.

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Inflammatory Skin Diseases Report Coverage 7
2.2 Acne Vulgaris - Overview 7
2.3 Rosacea - Overview 7
2.4 Chronic Urticaria Or Hives - Overview 7
3 Therapeutics Development 8
3.1 Acne Vulgaris 8
3.2 Rosacea 15
3.3 Chronic Urticaria Or Hives 19
4 Therapeutics Assessment 23
4.1 Acne Vulgaris 23
4.2 Rosacea 30
4.3 Chronic Urticaria Or Hives 38
5 Companies Involved in Therapeutics Development 45
5.1 Acne Vulgaris 45
5.2 Rosacea 61
5.3 Chronic Urticaria Or Hives 66
6 Dormant Projects 71
6.1 Acne Vulgaris 71
6.2 Rosacea 75
6.3 Chronic Urticaria Or Hives 76
7 Discontinued Products 77
7.1 Acne Vulgaris 77
7.2 Rosacea 77
7.3 Chronic Urticaria Or Hives 78
8 Product Development Milestones 79
8.1 Acne Vulgaris 79
8.2 Rosacea 90
8.3 Chronic Urticaria Or Hives 101
9 Appendix 112
9.1 Methodology 112
9.2 Coverage 112
9.3 Secondary Research 112
9.4 Primary Research 112
9.5 Expert Panel Validation 112
9.6 Contact Us 113
9.7 Disclaimer 113

1.1 List of Tables
Table 1: Number of Products under Development for Acne Vulgaris 8
Table 2: Number of Products under Development by Companies, Acne Vulgaris 10
Table 3: Number of Products under Development by Universities/Institutes, Acne Vulgaris 11
Table 4: Products under Development by Companies, Acne Vulgaris 12
Table 5: Products under Development by Universities/Institutes, Acne Vulgaris 14
Table 6: Number of Products under Development for Rosacea 15
Table 7: Number of Products under Development by Companies, Rosacea 17
Table 8: Products under Development by Companies, Rosacea 18
Table 9: Number of Products under Development for Chronic Urticaria Or Hives 19
Table 10: Number of Products under Development by Companies, Chronic Urticaria Or Hives 21
Table 11: Products under Development by Companies, Chronic Urticaria Or Hives 22
Table 12: Number of Products by Stage and Target, Acne Vulgaris 24
Table 13: Number of Products by Stage and Mechanism of Action, Acne Vulgaris 26
Table 14: Number of Products by Stage and Route of Administration, Acne Vulgaris 28
Table 15: Number of Products by Stage and Molecule Type, Acne Vulgaris 30
Table 16: Number of Products by Stage and Target, Rosacea 32
Table 17: Number of Products by Stage and Mechanism of Action, Rosacea 34
Table 18: Number of Products by Stage and Route of Administration, Rosacea 36
Table 19: Number of Products by Stage and Molecule Type, Rosacea 38
Table 20: Number of Products by Stage and Target, Chronic Urticaria Or Hives 39
Table 21: Number of Products by Stage and Mechanism of Action, Chronic Urticaria Or Hives 41
Table 22: Number of Products by Stage and Route of Administration, Chronic Urticaria Or Hives 42
Table 23: Number of Products by Stage and Molecule Type, Chronic Urticaria Or Hives 44
Table 24: Acne Vulgaris - Pipeline by 3SBio Inc, 45
Table 25: Acne Vulgaris - Pipeline by BioPharmX Inc, 45
Table 26: Acne Vulgaris - Pipeline by Braintree Laboratories Inc, 46
Table 27: Acne Vulgaris - Pipeline by Cassiopea SpA, 46
Table 28: Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, 47
Table 29: Acne Vulgaris - Pipeline by Daewoong Co Ltd, 47
Table 30: Acne Vulgaris - Pipeline by Deltanoid Pharmaceuticals Inc, 48
Table 31: Acne Vulgaris - Pipeline by ELORAC Inc, 48
Table 32: Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd, 49
Table 33: Acne Vulgaris - Pipeline by Galderma SA, 49
Table 34: Acne Vulgaris - Pipeline by Helix BioMedix Inc, 50
Table 35: Acne Vulgaris - Pipeline by Innovation Pharmaceuticals Inc, 50
Table 36: Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, 51
Table 37: Acne Vulgaris - Pipeline by LEO Pharma A/S, 51
Table 38: Acne Vulgaris - Pipeline by Melinta Therapeutics Inc, 52
Table 39: Acne Vulgaris - Pipeline by Novabiotics Ltd, 52
Table 40: Acne Vulgaris - Pipeline by Novan Inc, 53
Table 41: Acne Vulgaris - Pipeline by Novartis AG, 53
Table 42: Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, 54
Table 43: Acne Vulgaris - Pipeline by Pfizer Inc, 54
Table 44: Acne Vulgaris - Pipeline by Phagelux Inc, 55
Table 45: Acne Vulgaris - Pipeline by Phosphagenics Ltd, 55
Table 46: Acne Vulgaris - Pipeline by Photocure ASA, 56
Table 47: Acne Vulgaris - Pipeline by Promius Pharma LLC, 56
Table 48: Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, 57
Table49:AcneVulgaris-PipelinebyRealmTherapeuticsPlc, 57
Table50: Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 58
Table51: Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd, 58
Table52: Acne Vulgaris - Pipeline by Sun Pharmaceutical Industries Ltd, 59
Table 53: Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International Inc, 59
Table 54: Acne Vulgaris - Pipeline by Vyome Biosciences Pvt Ltd, 60
Table 55: Acne Vulgaris - Pipeline by XBiotech Inc, 60
Table 56: Rosacea - Pipeline by Almirall SA, 61
Table 57: Rosacea - Pipeline by Amorepacific Corp, 63
Table 58: Rosacea - Pipeline by BioPharmX Inc, 63
Table 59: Rosacea - Pipeline by Cutanea Life Sciences Inc, 63
Table 60: Rosacea - Pipeline by ELORAC Inc, 64
Table 61: Rosacea - Pipeline by Foamix Pharmaceuticals Ltd, 64
Table 62: Rosacea - Pipeline by Hovione FarmaCiencia SA, 66
Table 63: Rosacea - Pipeline by Promius Pharma LLC, 66
Table 64: Rosacea - Pipeline by Sol-Gel Technologies Ltd, 66
Table 65: Chronic Urticaria Or Hives - Pipeline by ELORAC Inc, 68
Table 66: Chronic Urticaria Or Hives - Pipeline by F. Hoffmann-La Roche Ltd, 68
Table 67: Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, 69
Table 68: Chronic Urticaria Or Hives - Pipeline by Fountain Biopharma Inc, 69
Table 69: Chronic Urticaria Or Hives - Pipeline by Genentech Inc, 70
Table 70: Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, 70
Table 71: Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, 71
Table 72: Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, 72
Table 73: Chronic Urticaria Or Hives - Pipeline by Novartis AG, 72
Table 74: Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, 73
Table 75: Acne Vulgaris - Dormant Projects, 74
Table 76: Rosacea - Dormant Projects, 80
Table 77: Chronic Urticaria Or Hives - Dormant Projects, 82
Table 78: Acne Vulgaris - Discontinued Products, 83
Table 79: Rosacea - Discontinued Products, 83
Table 80: Chronic Urticaria Or Hives - Discontinued Products, 84

1.2 List of Figures
Figure 1: Number of Products under Development for Acne Vulgaris 8
Figure 2: Number of Products under Development by Companies, Acne Vulgaris 9
Figure 3: Number of Products under Development for Rosacea 15
Figure 4: Number of Products under Development by Companies, Rosacea 16
Figure 5: Number of Products under Development for Chronic Urticaria Or Hives 19
Figure 6: Number of Products under Development by Companies, Chronic Urticaria Or Hives 20
Figure 7: Number of Products by Top 10 Targets, Acne Vulgaris 23
Figure 8: Number of Products by Stage and Top 10 Targets, Acne Vulgaris 23
Figure 9: Number of Products by Top 10 Mechanism of Actions, Acne Vulgaris 25
Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions, Acne Vulgaris 25
Figure 11: Number of Products by Routes of Administration, Acne Vulgaris 27
Figure 12: Number of Products by Stage and Routes of Administration, Acne Vulgaris 27
Figure 13: Number of Products by Molecule Types, Acne Vulgaris 29
Figure 14: Number of Products by Stage and Molecule Types, Acne Vulgaris 29
Figure 15: Number of Products by Top 10 Targets, Rosacea 30
Figure 16: Number of Products by Stage and Top 10 Targets, Rosacea 31
Figure 17: Number of Products by Top 10 Mechanism of Actions, Rosacea 33
Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions, Rosacea 33
Figure 19: Number of Products by Routes of Administration, Rosacea 35
Figure 20: Number of Products by Stage and Routes of Administration, Rosacea 35
Figure 21: Number of Products by Molecule Types, Rosacea 37
Figure 22: Number of Products by Stage and Molecule Types, Rosacea 37
Figure 23: Number of Products by Targets, Chronic Urticaria Or Hives 38
Figure 24: Number of Products by Stage and Targets, Chronic Urticaria Or Hives 39
Figure 25: Number of Products by Mechanism of Actions, Chronic Urticaria Or Hives 40
Figure 26: Number of Products by Stage and Mechanism of Actions, Chronic Urticaria Or Hives 40
Figure 27: Number of Products by Routes of Administration, Chronic Urticaria Or Hives 41
Figure 28: Number of Products by Stage and Top 10 Routes of Administration, Chronic Urticaria Or Hives 42
Figure 29: Number of Products by Molecule Types, Chronic Urticaria Or Hives 43
Figure 30: Number of Products by Stage and Molecule Types, Chronic Urticaria Or Hives 43

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *